You are here:

retigabine (Trobalt)

Advice

following a full submission:

retigabine (Trobalt®) is accepted for restricted use within NHS Scotland.

Indication under review: Adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and above with epilepsy.

SMC restriction: patients with refractory epilepsy. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.

In two placebo-controlled studies in patients with refractory epilepsy retigabine was superior to placebo in terms of the proportion of patients experiencing  50% reduction in partial seizure frequency per 28 days. An indirect comparison indicates that retigabine has similar efficacy to two other antiepileptic drugs used as adjunctive therapy.

Drug Details

Drug Name: retigabine (Trobalt)
SMC Drug ID: 712/11
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Adjunctive treatment of partial onset seizures without secondary generalisation in adults aged 18 years and above with epilepsy
BNF Category:
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 July 2011

Back